

Drug Enforcement Administration, Justice

§ 1308.15

(22) Ethinamate	2545	(2) Diethylpropion	1610
(23) Ethyl loflazepate	2758	(3) Fencamfamin	1760
(24) Fludiazepam	2759	(4) Fenproporex	1575
(25) Flunitrazepam	2763	(5) Mazindol	1605
(26) Flurazepam	2767	(6) Mefenorex	1580
(27) Fospropofol	2138	(7) Modafinil	1680
(28) Halazepam	2762	(8) Pemoline (including	
(29) Haloxazolam	2771	organometallic complexes and	
(30) Ketazolam	2772	chelates thereof)	1530
(31) Lemborexant	2245	(9) Phentermine	1640
(32) Loprazolam	2773	(10) Pipradrol	1750
(33) Lorazepam	2885	(11) Serdexmethylphenidate	1729
(34) Lormetazepam	2774	(12) Sibutramine	1675
(35) Mebutamate	2800	(13) Solriamfetol (2-amino-3-	
(36) Medazepam	2836	phenylpropyl carbamate;	
(37) Meprobamate	2820	benzenepropanol, beta-amino-,	
(38) Methohexital	2264	carbamate (ester))	1650
(39) Methylphenobarbital		(14) SPA ((-)-1-dimethylamino-	
(mephobarbital)	2250	1,2-diphenylethane)	1635
(40) Midazolam	2884	(g) <i>Other substances.</i> Unless specifi-	
(41) Nimetazepam	2837	cally excepted or unless listed in an-	
(42) Nitrazepam	2834	other schedule, any material, com-	
(43) Nordiazepam	2838	pound, mixture or preparation which	
(44) Oxazepam	2835	contains any quantity of the following	
(45) Oxazolam	2839	substances, including its salts:	
(46) Paraldehyde	2585	(1) Pentazocine	9709
(47) Petrichloral	2591	(2) Butorphanol (including its	
(48) Phenobarbital	2285	optical isomers)	9720
(49) Pinazepam	2883	(3) Eluxadolone (5-[[[(2 <i>S</i>)-2-	
(50) Prazepam	2764	amino-3-[4-aminocarbonyl]-2,6-	
(51) Quazepam	2881	dimethylphenyl]-1-	
(52) Remimazolam	2846	oxopropyl][(1 <i>S</i>)-1-(4-phenyl-1 <i>H</i> -	
(53) Suvorexant	2223	imidazol-2-	
(54) Temazepam	2925	yl)ethyl]amino]methyl]-2-	
(55) Tetrazepam	2886	methoxybenzoic acid) (includ-	
(56) Triazolam	2887	ing its optical isomers) and its	
(57) Zaleplon	2781	salts, isomers, and salts of iso-	
(58) Zolpidem	2783	mers (9725)..	
(59) Zopiclone	2784		

(d) [Reserved]

(e) *Lorcaserin.* Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

(1) Lorcaserin	1625
----------------------	------

(f) *Stimulants.* Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

(1) Cathine ((+)-	
norpseudoephedrine)	1230

[39 FR 22143, June 20, 1974]

EDITORIAL NOTE: For FEDERAL REGISTER citations affecting § 1308.14, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.govinfo.gov.

§ 1308.15 Schedule V.

(a) Schedule V shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

(b) *Narcotic drugs.* Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs and their salts, as set forth below:

(1) [Reserved]

§ 1308.21

21 CFR Ch. II (4–1–23 Edition)

(2) [Reserved]

(c) *Narcotic drugs containing non-narcotic active medicinal ingredients.* Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:

(1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.

(2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.

(3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.

(4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.

(5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.

(6) Not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

(d) *Stimulants.* Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

(1) Pyrovalerone 1485.
(2) [Reserved].

(e) *Depressants.* Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:

(1) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) 2710
(2) Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester) 2720
(3) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester] 2779
(4) Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one) 2401
(5) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide] 2746
(6) Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl)-benzamide] 2790
(7) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid] 2782

[39 FR 22143, June 20, 1974, as amended at 43 FR 38383, Aug. 28, 1978; 44 FR 40888, July 13, 1979; 47 FR 49841, Nov. 3, 1982; 50 FR 8108, Feb. 28, 1985; 52 FR 5952, Feb. 27, 1987; 53 FR 10870, Apr. 4, 1988; 56 FR 61372, Dec. 3, 1991; 67 FR 62370, Oct. 7, 2002; 70 FR 43635, July 28, 2005; 74 FR 23790, May 21, 2009; 76 FR 77899, Dec. 15, 2011; 81 FR 29491, May 12, 2016; 83 FR 48953, Sept 28, 2018; 85 FR 5562, Jan. 31, 2020; 85 FR 13746, Mar. 10, 2020; 85 FR 51645, Aug. 21, 2020; 87 FR 32996, June 1, 2022]

EXCLUDED NONNARCOTIC SUBSTANCES

§ 1308.21 Application for exclusion of a nonnarcotic substance.

(a) Any person seeking to have any nonnarcotic drug that may, under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301), be lawfully sold over the counter without a prescription, excluded from any schedule, pursuant to section 201(g)(1) of the Act (21 U.S.C. 811(g)(1)), may apply to the Drug and Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration. See the Table of DEA Mailing Addresses in §1321.01 of this chapter for the current mailing address.